ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herve, P
Right arrow Articles by Duroux, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herve, P
Right arrow Articles by Duroux, P
Eur Respir J 1998; 11: 1153-1166
Copyright © ERS Journals Ltd 1998

Original Articles

Pulmonary vascular disorders in portal hypertension

P Herve, D Lebrec, F Brenot, G Simonneau, M Humbert, O Sitbon, and P Duroux

The wide spectrum of pulmonary vascular disorders in liver disease and portal hypertension ranges from the hepatopulmonary syndrome characterized by intrapulmonary vascular dilatations, to pulmonary hypertension (portopulmonary hypertension), in which pulmonary vascular resistance is elevated. Since hepatopulmonary syndrome and portopulmonary hypertension have been reported in patients with nonhepatic portal hypertension, the common factor that determines their development must be portal hypertension. The clinical presentations are very different, with gas exchange impairment in the hepatopulmonary syndrome and haemodynamic failure in portopulmonary hypertension. The severity of hepatopulmonary syndrome seems to parallel the severity of liver failure, whereas no simple relationship has been identified between hepatic impairment and the severity of portopulmonary hypertension. Resolution of hepatopulmonary syndrome is common after liver transplantation, which has an uncertain effect in portopulmonary hypertension. The pathophysiology of both syndromes may involve vasoactive mediators and angiogenic factors.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
The Task Force for the Diagnosis and Treatment of, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension
Eur. Respir. J., December 1, 2009; 34(6): 1219 - 1263.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al.
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)
Eur. Heart J., October 2, 2009; 30(20): 2493 - 2537.
[Full Text] [PDF]

Home page
 BloodHome page
E. S. Shao, L. Lin, Y. Yao, and K. I. Bostrom
Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells
Blood, September 3, 2009; 114(10): 2197 - 2206.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. Simonneau, I. M. Robbins, M. Beghetti, R. N. Channick, M. Delcroix, C. P. Denton, C. G. Elliott, S. P. Gaine, M. T. Gladwin, Z.-C. Jing, et al.
Updated clinical classification of pulmonary hypertension.
J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S43 - S54.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
H. Yeshua, L. M. Blendis, and R. Oren
Pulmonary Manifestations of Liver Diseases
Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2009; 13(1): 60 - 69.
[Abstract] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. Le Pavec, R. Souza, P. Herve, D. Lebrec, L. Savale, C. Tcherakian, X. Jais, A. Yaici, M. Humbert, G. Simonneau, et al.
Portopulmonary Hypertension: Survival and Prognostic Factors
Am. J. Respir. Crit. Care Med., September 15, 2008; 178(6): 637 - 643.
[Abstract] [Full Text] [PDF]

Home page
 Cleveland Clinic Journal of MedicineHome page
K. L. SWANSON and M. J. KROWKA
Screen for portopulmonary hypertension, especially in liver transplant candidates
Cleveland Clinic Journal of Medicine, February 1, 2008; 75(2): 121 - 136.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. M. Hoeper, H. J. Seyfarth, G. Hoeffken, H. Wirtz, E. Spiekerkoetter, M. W. Pletz, T. Welte, and M. Halank
Experience with inhaled iloprost and bosentan in portopulmonary hypertension
Eur. Respir. J., December 1, 2007; 30(6): 1096 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J. Moorman, M. Saad, S. Kosseifi, and G. Krishnaswamy
Hepatitis C Virus and the Lung: Implications for Therapy
Chest, October 1, 2005; 128(4): 2882 - 2892.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. H. Henriksen, S. Moller, S. Fuglsang, and F. Bendtsen
Detection of early central circulatory transits in patients with cirrhosis by gamma variate fit of indicator dilution profiles
Am J Physiol Gastrointest Liver Physiol, April 1, 2005; 288(4): G677 - G684.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. M. Hoeper, M. Halank, C. Marx, G. Hoeffken, H. J. Seyfarth, J. Schauer, J. Niedermeyer, and J. Winkler
Bosentan therapy for portopulmonary hypertension
Eur. Respir. J., March 1, 2005; 25(3): 502 - 508.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Naeije and A. T. Dinh-Xuan
From the authors
Eur. Respir. J., January 1, 2005; 25(1): 212 - 212.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Rodriguez-Roisin, M.J. Krowka, Ph. Herve, M.B. Fallon, and on behalf of the ERS Task Force Pulmonary-Hepatic
Pulmonary-Hepatic vascular Disorders (PHD)
Eur. Respir. J., November 1, 2004; 24(5): 861 - 880.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Minder, M. Fischler, B. Muellhaupt, M.P. Zalunardo, R. Jenni, P-A. Clavien, and R. Speich
Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension
Eur. Respir. J., October 1, 2004; 24(4): 703 - 707.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A.T. Dinh-Xuan and R. Naeije
The hepatopulmonary syndrome: NO way out?
Eur. Respir. J., May 1, 2004; 23(5): 661 - 662.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
B. Sztrymf, A. Rabiller, H. Nunes, L. Savale, D. Lebrec, A. Le Pape, V. de Montpreville, M. Mazmanian, M. Humbert, and P. Herve
Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats
Eur. Respir. J., May 1, 2004; 23(5): 752 - 758.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
F S Benjaminov, M Prentice, K W Sniderman, S Siu, P Liu, and F Wong
Portopulmonary hypertension in decompensated cirrhosis with refractory ascites
Gut, September 1, 2003; 52(9): 1355 - 1362.
[Abstract] [Full Text]

Home page
 ChestHome page
R. Budhiraja and P. M. Hassoun
Portopulmonary Hypertension: A Tale of Two Circulations
Chest, February 1, 2003; 123(2): 562 - 576.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
P Schenk, V Fuhrmann, C Madl, G Funk, S Lehr, O Kandel, and C Muller
Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences
Gut, December 1, 2002; 51(6): 853 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
N. Galie, A. Manes, and A. Branzi
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension
Eur. Respir. J., October 1, 2002; 20(4): 1037 - 1049.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. Rabiller, H. Nunes, D. Lebrec, K. A. Tazi, M. Wartski, E. Dulmet, J.-M. Libert, C. Mougeot, R. Moreau, M. Mazmanian, et al.
Prevention of Gram-Negative Translocation Reduces the Severity of Hepatopulmonary Syndrome
Am. J. Respir. Crit. Care Med., August 15, 2002; 166(4): 514 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Humbert, P. Labrune, O. Sitbon, C. Le Gall, J. Callebert, P. Herve, D. Samuel, R. Machado, R. Trembath, L. Drouet, et al.
Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis
Eur. Respir. J., July 1, 2002; 20(1): 59 - 65.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. L. Swanson and M. J. Krowka
Arterial Oxygenation Associated With Portopulmonary Hypertension*
Chest, June 1, 2002; 121(6): 1869 - 1875.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
N. Galie, M. Humbert, J.-L. Vachiery, C. Vizza, M. Kneussl, A. Manes, O. Sitbon, A. Torbicki, M. Delcroix, R. Naeije, et al.
Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1496 - 1502.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G. Stratakos, K. Malagari, E. Broutzos, E. Zakynthinos, C. Roussos, and S. Papiris
Dyspnoea and cyanosis in a cirrhotic patient
Eur. Respir. J., April 1, 2002; 19(4): 780 - 783.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. DELCLAUX, B. MAHUT, F. ZERAH-LANCNER, C. DELACOURT, S. LAOUD, D. CHERQUI, C. DUVOUX, A. MALLAT, and A. HARF
Increased Nitric Oxide Output from Alveolar Origin during Liver Cirrhosis versus Bronchial Source during Asthma
Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 332 - 337.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. NUNES, D. LEBREC, M. MAZMANIAN, F. CAPRON, J. HELLER, K. A. TAZI, E. ZERBIB, E. DULMET, R. MOREAU, A. T. DINH-XUAN, et al.
Role of Nitric Oxide in Hepatopulmonary Syndrome in Cirrhotic Rats
Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 879 - 885.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. J. Krowka, G. A. Wiseman, O. L. Burnett, J. R. Spivey, T. Therneau, M. K. Porayko, and R. H. Wiesner
Hepatopulmonary Syndrome : A Prospective Study of Relationships Between Severity of Liver Disease, PaO2 Response to 100% Oxygen, and Brain Uptake After 99mTc MAA Lung Scanning
Chest, September 1, 2000; 118(3): 615 - 624.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
R.H. Lachmann, D.G.D. Wight, D.J. Lomas, N.C. Fisher, J.P. Schofield, E. Elias, and T.M. Cox
Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features
QJM, April 1, 2000; 93(4): 237 - 244.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M J KROWKA
Hepatopulmonary syndromes
Gut, January 1, 2000; 46(1): 1 - 4.
[Full Text] [PDF]

Home page
 ThoraxHome page
A J Peacock
Rare diseases bullet 5: Primary pulmonary hypertension
Thorax, December 1, 1999; 54(12): 1107 - 1118.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the European Respiratory Society.